Tweets
A full day of ACR. Now comes the conversation.
RheumNow’s daily recaps begin Sunday, Nov. 8 and continue through Wednesday, Nov. 11.
6 PM ET / 5 PM CT / 3 PM PT
Sharp perspectives. Thoughtful debate. Join us LIVE on X, YouTube, Facebook or LinkedIn.
The abstracts start the https://t.co/Ts2IUj4oyb
Dr. John Cush @RheumNow ( View Tweet )
11 minutes 25 seconds ago
Jamshaid & Gomaa (Tirzepatide vs semaglutide cohort): tirzepatide was associated with lower 1-year and 3-year risks of treatment-defined flare proxies compared with semaglutide. @rheumnow #ACR2026 Abstract#2641
Audrey Gibson @Gibson_RheumPAC ( View Tweet )
22 minutes 55 seconds ago
Jamshaid & Gomaa (Tirzepatide vs semaglutide cohort): A large real-world comparison found less steroid use with tirzepatide than semaglutide at 3 years: 27.2% vs 37.5%.@rheumnow #ACR2026 Abstract#2641
Audrey Gibson @Gibson_RheumPAC ( View Tweet )
22 minutes 57 seconds ago
Jamshaid & Gomaa (Tirzepatide vs semaglutide cohort): Tirzepatide vs semaglutide in inflammatory arthritis: steroid use at 1 year was 19.1% vs 22.5% in matched cohorts. @rheumnow #ACR2026 Abstract#2641
Audrey Gibson @Gibson_RheumPAC ( View Tweet )
22 minutes 59 seconds ago
Weber et al. (TOGETHER PsO&PsA): 30% lower predicted 10-year CVD risk vs pts IXE mono. suggest that targeting both inflammatory and metabolic pathways may improve CV benefit and potentially reduce long-term CV burden in this high-risk population. @rheumnow #ACR2026 Abstract#2299
Audrey Gibson @Gibson_RheumPAC ( View Tweet )
23 minutes 2 seconds ago
Dörner et al: The NEPTUNUS extension examines longer-term ianalumab treatment in Sjögren's disease after positive phase 3 trials. Durability, safety and sustained disease control are the questions to watch. @rheumnow #ACR2026 Abstract#LB14
Audrey Gibson @Gibson_RheumPAC ( View Tweet )
23 minutes 3 seconds ago
Anti-drug antibodies against inebilizumab were not impactful in MITIGATE
Incidence of ADAs similar in INE arm (8.8%) and PBO arm (7.5%)
NO impact of ADA on drug concentrations
NO efficacy difference by flares in ADA+/- INE pt
@RheumNow #ACR26 #ABST2109 https://t.co/rfOlUMGc2N
Brian Jaros, MD @Dr_Brian_MD ( View Tweet )
23 minutes 8 seconds ago
TOGETHER-PsA (n=271): week 36, 31.7% on ixekizumab + tirzepatide vs 0.8% on ixekizumab alone achieved BOTH ACR50 and >=10% weight loss. Adding tirzepatide to ixe improved PsA disease control as early as WK4 alongside weight loss in overweight or obese pts. #2297 #ACR26 @Rheumnow
Mrinalini Dey @DrMiniDey ( View Tweet )
23 minutes 12 seconds ago
Myocardial mayhem: IIMs assoc with cardiac involv such as arrhythmia, heart block, peri or myocarditis.
Cohort of 110 IIM pts , 14.5% with cardiac features. Myocarditis and arrhythmia most common. Majority @ IIM Dx.
Predictors: male and overlap myositis Ab2595 #ACR26 @RheumNow
Daric Mueller, PA-C @rheumPAC ( View Tweet )
23 minutes 13 seconds ago
What can we learn from large IgG4 dataset?
Epic Cosmos reviewed for IgG4 ICD codes
Total: 6.4k IgG4-RD & 128k matched controls
IgG4 patients:
- more HTN, HLD, DMII
- more MI, CVA, VTE
- more infections
- higher incident malignancy
@RheumNow #ACR26 #ABST2108 https://t.co/7mUOItGONP
Brian Jaros, MD @Dr_Brian_MD ( View Tweet )
23 minutes 16 seconds ago
Weber et al. (TOGETHER cardiometabolic analysis): ixekizumab + tirzepatide was associated with about 30% lower predicted 10-year CV risk vs ixekizumab alone at week 36. @rheumnow #ACR2026 Abstract#2299 https://t.co/NmulNKUwLL
Audrey Gibson @Gibson_RheumPAC ( View Tweet )
23 minutes 24 seconds ago
Pugnet et al: Randomized phase 2 data with oral factor B inhibitor iptacopan suggest high remission rates at 24 weeks in active ANCA vasculitis. Could alternative complement inhibition expand our options? @rheumnow #ACR2026 Abstract#LB16
Audrey Gibson @Gibson_RheumPAC ( View Tweet )
23 minutes 26 seconds ago
Weber et al: Ixekizumab + tirzepatide improved CV risk factors and calculated CV risk beyond ixekizumab alone in psoriatic disease with obesity. Not proven fewer CV events, but a powerful reason to look beyond joints. @rheumnow #ACR2026 #ACRBest Abstract#2299
Audrey Gibson @Gibson_RheumPAC ( View Tweet )
23 minutes 29 seconds ago
Data from hopkins lupus cohort compared early vs late CV events in SLE
Highest rate of CVEs within 2 yrs of dx; 8x higher vs. pre-Dx period
RFs for early CVEs - >45yo, obesity, DM, HTN, hyperlipid, LAC
RFs for late CVEs similar to early + smoking, low c3
@RheumNow #ACR26 Abs2247 https://t.co/FIyB59930J
Links:
sheila @RHEUMarampa ( View Tweet )
23 minutes 32 seconds ago
Jamshaid et al: Tirzepatide vs semaglutide in inflammatory arthritis: 3-year steroid use was 27.2% vs 37.5%. Less treatment escalation is intriguing. @rheumnow #ACR2026 #ACRBest Abstract#2641
Audrey Gibson @Gibson_RheumPAC ( View Tweet )
23 minutes 38 seconds ago